Meeting Banner
Abstract #1088

Metabolomic Evaluations of Human Prostate Tissue from mp-MRI/US Fusion Biopsy

Lindsey A. Vandergrift1, Taylor L. Fuss1, Yannick Berker1, Shulin Wu1, Chris Dietz1,2, Felix Ehret1,2, Sarah S. Dinges1,3, Edouard Nicaise4, Piet Habbel3, Johannes Nowak2, Chin-Lee Wu1, Adam Feldman4, and Leo L. Cheng1

1Pathology, Massachusetts General Hospital, Charlestown, MA, United States, 2Radiology, University of Wurzburg, Wurzburg, Germany, 3Oncology, Charite Medical University, Berlin, Germany, 4Urology, Massachusetts General Hospital, Boston, MA, United States

Heterogeneity and clinical insignificance of prostate cancer (PCa) lesions challenges diagnosis and management. Introduction of the multi-parameter (mp)-MRI/ultrasound fusion-guided biopsy increased detection of clinically significant cancer. Prostate MRI lesions receive a PI-RADS score based on likelihood of being cancer-positive. Fusing MRI images with live ultrasound guides biopsy from the targeted area. Previously, PI-RADS score has been correlated with clinical significance of cancer and morphological variations in PCa lesions. We studied PI-RADS score according to tissue MRS-based metabolomics. Metabolic differences between Target and Non-target cores, regardless if Targets were cancer-positive, support the assumption that targeted areas fundamentally differ from non-targeted areas.

This abstract and the presentation materials are available to members only; a login is required.

Join Here